Form 4: Progyny COO Receives Significant Equity Awards

Progyny's Chief Operating Officer, Melissa B. Cummings, was granted 45,454 restricted stock units and 66,289 stock options as part of an annual merit award.

Summary

• Melissa B. Cummings, Chief Operating Officer of Progyny, Inc. (PGNY), received an annual merit grant of equity awards.
• The grant included 45,454 shares of common stock underlying restricted stock units (RSUs) at a price of $0.
• The grant also included 66,289 stock options with an exercise price of $17.6 per share and a price of $0 for the derivative security itself.
• Both the RSUs and stock options were granted on March 2, 2026, under the Issuer's 2019 Equity Incentive Plan.
• The RSUs and stock options will vest 33% on the first anniversary of the grant date, with the remainder vesting quarterly thereafter through the third anniversary, subject to continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents routine executive compensation that aligns management's long-term interests with shareholder value, without indicating any new operational or financial performance changes.

Positives

• The grant of 45,454 restricted stock units and 66,289 stock options aligns the Chief Operating Officer's interests with those of shareholders, incentivizing long-term performance.
• The awards are part of an annual merit grant, indicating ongoing executive compensation and retention strategies.

Future Outlook

The vesting schedule for the equity awards extends through the third anniversary of the grant date, indicating an expectation of continued service from the Chief Operating Officer and a long-term incentive structure.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units and stock options, are a standard component of executive compensation packages across various industries. These grants are designed to align the interests of executives with those of shareholders by tying a significant portion of their compensation to the company's long-term stock performance and continued service.

Comparison to Industry Standards

• Executive equity grants are a common practice in the healthcare technology sector, similar to companies like Teladoc Health (TDOC) or Livongo Health (LVGO, now part of TDOC), where performance-based incentives are crucial for retaining key talent.
• The vesting schedule over three years is typical for such awards, aiming to ensure executive retention and sustained performance contributions, comparable to practices seen at many publicly traded companies.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Operating Officer's incentives with long-term shareholder value creation.
• Employees: This grant is part of an annual merit award, which may signal a consistent approach to executive compensation and talent retention within the company.

Next Steps

• The Chief Operating Officer's continued service is required for the vesting of the restricted stock units and stock options over the next three years.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive as part of their compensation package. While it positively aligns management's interests with shareholders, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as it reflects a standard corporate event without immediate implications for stock valuation beyond existing expectations.

Keywords

Progyny, PGNY, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Insider Transaction, Form 4